[1] KOMURA K,SWEENEY C J,INAMOTO T,et al. Current treatment strategies for advanced prostate cancer[J]. Int J Urol,2018,25(3): 220-231.
[2] HEIDENREICH A,BELLMUNT J,BOLLA M,et al. EAU guidelines on prostate cancer. Part I:screening,diagnosis,and treatment of clinically localised disease[J]. Actas Urol Esp,2011,35(9):501-514.
[3] KLOTZ L,ZHANG L,LAM A,et al. Clinical results of long-term follow-up of a large,active surveillance cohort with localized prostate cancer[J]. J Clin Oncol,2010,28(1):126-131.
[4] HE L,HANNON G J. MicroRNAs:small RNAs with a big role in gene regulation[J]. Nat Rev Genet,2004,5(7):522-531.
[5] KOZOMARA A,GRIFFITHS-JONES S.miRBase:annotating high confidence microRNAs using deep sequencing data[J]. Nucleic Acids Res,2014,42(Database issue):D68-D73.
[6] HA M,KIM V N. Regulation of microRNA biogenesis[J]. Nat Rev Mol Cell Biol,2014,15(8):509-524.
[7] MATSUZAKI K,FUJITA K,TOMIYAMA E,et al. MiR-30b-3p and miR-126-3p of urinary extracellular vesicles could be new biomarkers for prostate cancer[J]. Transl Androl Urol,2021,10(4):1918-1927.
[8] SHIN S,PARK Y H,JUNG S H,et al. Urinary exosome microRNA signatures as a noninvasive prognostic biomarker for prostate cancer[J]. NPJ Genom Med,2021,6(1):45.
[9] FABRIS L,CEDER Y,CHINNAIYAN A M,et al. The potential of micrornas as prostate cancer biomarkers[J]. Eur Urol,2016,70(2): 312-322.
[10] FREDSOE J,RASMUSSEN A K I,THOMSEN A R,et al. Diagnostic and prognostic microRNA biomarkers for prostate cancer in cell-free urine[J]. Eur Urol Focus,2018,4(6):825-833.
[11] LIU R S C,OLKHOV-MITSEL E,JEYAPALA R,et al. Assessment of serum microrna biomarkers to predict reclassification of prostate cancer in patients on active surveillance[J]. J Urol,2018,199(6): 1475-1481.
[12] SUN Y,CHEN G,HE J,et al. Clinical significance and potential molecular mechanism of miRNA-222-3p in metastatic prostate cancer[J]. Bioengineered,2021,12(1):325-340.
[13] ANDERSEN C L,JENSEN J L,ORNTOFT T F. Normalization of real-time quantitative reverse transcription-PCR data:a model-based variance estimation approach to identify genes suited for normalization,applied to bladder and colon cancer data sets[J]. Cancer Res,2004,64(15):5245-5250.
[14] FREDS?覫E J,RASMUSSEN A K I,MOURITZEN P,et al. A five-microRNA model(pCaP)for predicting prostate cancer aggressiveness using cell-free urine[J]. Int J Cancer,2019,145(9):2558-2567.
[15] ZHANG S,LIU C,ZOU X,et al. MicroRNA panel in serum reveals novel diagnostic biomarkers for prostate cancer[J]. PeerJ,2021,9:e11441.
[16] LIN Y,CAO H,TIAN Y,et al. MiR-24-3p stimulates migration,invasion and proliferation of prostate cancer cells by targeting suppressor of cytokine signaling 6[J]. Int J Clin Exp Pathol,2018,11(3): 1803-1810.
[17] LI X,HAN X,WEI P,et al. Knockdown of lncRNA CCAT1 enhances sensitivity of paclitaxel in prostate cancer via regulating miR-24-3p and FSCN1[J]. Cancer Biol Ther,2020,21(5):452-462.
[18] KREBS M,SOLIMANDO A G,KALOGIROU C,et al. MiR-221-3p regulates VEGFR2 expression in high-risk prostate cancer and represents an escape mechanism from sunitinib in vitro[J]. J Clin Med,2020,9(3):670-677.
[1]魏强,齐灿,罗飞,等.转移性去势抵抗性前列腺癌患者多西他赛化疗的预后分析[J].天津医科大学学报,2013,19(05):390.
[2]杨帮东,姜行康,齐 灿,等.尿液中PCA3评分对前列腺癌早期诊断的临床意义[J].天津医科大学学报,2013,19(06):487.
YANG Bang-dong,JIANG Xing-kang,QI Can,et al.Clinical significance of urinary PCA3 score to diagnose prostate cancer[J].Journal of Tianjin Medical University,2013,19(02):487.
[3]刘利维,刘春雨. MicroRNAs 与前列腺癌的表观遗传学研究进展[J].天津医科大学学报,2014,20(01):74.
[4]王 超,余泉峰,徐 勇,等.经直肠超声造影诊断前列腺癌的临床分析[J].天津医科大学学报,2014,20(05):375.
WANG Chao,YU Quan-feng,XU Yong,et al.Clinical analysis of contrast-enhanced transrectal ultrasonography for the diagnosis of prostate cancer[J].Journal of Tianjin Medical University,2014,20(02):375.
[5]张晓会,张志宏,徐 勇,等.合并症对局限性或局部晚期前列腺癌患者早期生存的影响[J].天津医科大学学报,2014,20(05):379.
ZHANG Xiao-hui,ZHANG Zhi-hong,XU Yong,et al. Influence of complications on early survival of patients with localized or locally advanced prostate cancer[J].Journal of Tianjin Medical University,2014,20(02):379.
[6]盛 镔,张 蒙,马鹏德,等.核糖体蛋白L37在前列腺癌中的表达及临床意义[J].天津医科大学学报,2015,21(05):401.
SHENG Bin,ZHANG Meng,MA Peng-de,et al.Expression of ribosomal protein L37 in prostate cancer and its clinical significance[J].Journal of Tianjin Medical University,2015,21(02):401.
[7]管明秀,周云丽,王 萌,等.TuM2-PK,tPSA,fPSA/tPSA和PSAD对PSA灰区前列腺癌诊断价值的比较[J].天津医科大学学报,2016,22(02):140.
GUAN Ming-xiu,ZHOU Yun-li,WANG-Meng,et al.Diagnostic implication of TuM2-PK, tPSA, fPSA/tPSA ratio and PSAD for prostate cancer in PSA gray area[J].Journal of Tianjin Medical University,2016,22(02):140.
[8]李 江,张恩龙,赵 阳,等.前列腺癌靶向磁共振成像和光热治疗的实验研究[J].天津医科大学学报,2017,23(02):93.
LI Jiang,ZHANG En-long,ZHAO Yang,et al.?Experimental research of targeted magnetic resonance imaging and photo thermal therapy for prostate cancer [J].Journal of Tianjin Medical University,2017,23(02):93.
[9]张一然,潘盼,连振鹏,等.磁共振扫描对经直肠超声引导前列腺穿刺活检的影响[J].天津医科大学学报,2017,23(02):99.
ZHANG Yi-ran,PAN Pan,LIAN Zhen-peng,et al.Effect of magnetic resonance imaging scan on the?transrectal ultrasound?prostate biopsy[J].Journal of Tianjin Medical University,2017,23(02):99.
[10]薄志强,孙桂江,王 丽,等.CtBP2异常表达对前列腺癌PC3细胞增殖效应影响的研究[J].天津医科大学学报,2017,23(02):103.
BO Zhi-qiang,SUNGui-jiang,WANG Li,et al.Effect of abnormal expression of CtBP2 on the proliferation of prostate cancer cell line PC3[J].Journal of Tianjin Medical University,2017,23(02):103.